{"filings":[{"id":1342676,"accession_number":"0001104659-26-079087","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2026-06-30T11:36:57+00:00","items":["5.02"],"status":"ready","headline":"Palvella Therapeutics appoints Matthew Pauls to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 7 to 8 members; Pauls appointed as Class I director effective June 29, 2026.","Pauls is CEO of Savara (NASDAQ: SVRA) and has led rare disease biopharma companies including Strongbridge.","He received an option to purchase 6,000 shares vesting monthly over 36 months under the Director Compensation Policy.","Board determined Pauls is independent under Nasdaq listing rules; no related party transactions disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1066477,"accession_number":"0001104659-26-074338","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2026-06-16T12:30:30+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Palvella stockholders approve 750K-share increase to 2024 equity plan; re-elect three directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2024 equity incentive plan, increasing authorized shares by 750,000. Votes: 7,692,709 for, 2,475,470 against.","Re-elected George M. Jenkins, Todd C. Davis, and John Doux, M.D. as Class III directors until 2029 annual meeting.","Ratified Ernst & Young as independent auditor for 2026 fiscal year: 11,557,687 for, 13,216 against, 6,566 abstain.","Advisory vote on executive compensation approved (10,008,180 for); board determined future say-on-pay every year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":555476,"accession_number":"0001193125-26-232717","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2026-05-20T20:35:15+00:00","items":["8.01","9.01"],"status":"ready","headline":"Palvella Phase 3 SELVA: 100% of children responded; NDA filing on track for H2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 SELVA: 100% of 13 children (6-11 yrs) rated 'Much Improved' or better on mLM-IGA at Week 24 (mean +2.46, p<0.001).","87% (20/23) with baseline leaking/bleeding showed 'Much Improved' or better on leaking/bleeding scale at Week 24 (mean +2.48).","Blinded review: pre-treatment stability, then 48% max improvement after 24 weeks (mean mLM-MCSS from 9.9 to 6.6).","Phase 2 TOIVA: stat sig improvements in cVM-MCSS Height (mean -1.50) and Appearance (mean -1.43) at Week 24 (p<0.001).","NDA submission for microcystic LMs planned H2 2026; Phase 3 for cutaneous VMs starts H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":452478,"accession_number":"0001193125-26-225317","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2026-05-15T11:30:16+00:00","items":["8.01","9.01"],"status":"ready","headline":"Palvella reports Phase 2 TOIVA data: 100% bleed improvement, p=0.003","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["100% of patients with bleeding at baseline showed statistically significant improvement on cVM-IGA Bleeding at Week 12 (mean +2.5, p=0.003).","All bleeding patients reported 'satisfied' or 'very satisfied' with QTORIN rapamycin on Treatment Satisfaction Questionnaire at Week 12.","Baseline patient interviews show QoL burden includes pain, physical limitations, emotional distress from lesion visibility.","QTORIN rapamycin could become first FDA-approved therapy for cutaneous venous malformations, targeting >75,000 U.S. patients.","Data presented at 83rd SID Annual Meeting in Chicago on May 15, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":50167,"accession_number":"0001193125-26-220607","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2026-05-13T11:30:15+00:00","items":["8.01"],"status":"ready","headline":"Palvella Therapeutics approved to uplist to Nasdaq Global Market on May 13","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq approval for transfer from Capital Market to Global Market received May 11, 2026.","Effective at open of business on May 13, 2026; ticker PVLA unchanged.","Company will trade on the more prestigious Nasdaq Global tier."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93856,"accession_number":"0001193125-26-210605","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Palvella Q1 net loss $15.8M; cash $261.9M after $230M equity raise; NDA on track H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $15.8M ($1.20/share) vs $8.2M ($0.74) in Q1 2025; R&D spend $9.3M up from $4.1M.","Cash, cash equivalents & short-term investments $261.9M as of Mar 31, following $230M oversubscribed equity offering in Feb 2026.","FDA pre-NDA meeting granted for QTORIN rapamycin in microcystic LMs; NDA submission on track for H2 2026.","Phase 3 SELVA study positive topline results; Phase 2 LOTU initiated; Phase 3 for cutaneous VMs and Phase 2 for DSAP planned H2 2026.","Appointed Jennifer McDonough (SVP Market Access) and Kent Taylor (SVP Sales) to strengthen pre-launch commercialization team."],"consensus_eps_estimate":-0.9508,"consensus_eps_actual":-1.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93855,"accession_number":"0001193125-26-151979","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Palvella Therapeutics appoints John Doux, M.D. to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased to 7 members; Dr. Doux appointed as Class III director with term expiring at 2026 Annual Meeting.","Dr. Doux is a board-certified dermatologist and analyst at Palo Alto Investors LP since 2004.","Granted option to purchase 6,000 shares vesting in equal monthly installments over 36 months.","Previously served on Palvella's board before reverse merger (2019-2022).","Board determined Dr. Doux independent under Nasdaq listing rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93854,"accession_number":"0001193125-26-144540","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Palvella posts April 2026 corporate presentation; no material updates disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation titled 'First-in-disease therapies for patients with rare diseases'.","Filing does not contain specific financial or clinical data points.","No changes to business outlook, guidance, or pipeline disclosed.","Presentation is intended for investor meetings; no material new information provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105810,"accession_number":"0001193125-26-133332","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Palvella reports FY2025 net loss $41.7M; Phase 3 SELVA success paves path to NDA in H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $41.7M ($3.71 per share) vs $17.4M ($7.83) in FY2024; R&D $22.8M, G&A $15.8M.","Cash $58M at Dec 31; pro forma cash ~$274M after $230M oversubscribed equity offering closed Feb 2026.","Phase 3 SELVA for microcystic LMs met primary endpoint (p<0.001); NDA submission on track for H2 2026.","Phase 3 trial for cutaneous venous malformations planned H2 2026; Phase 2 for angiokeratomas in Q2 2026.","Company to announce fourth QTORIN rapamycin indication and third platform product in H2 2026."],"consensus_eps_estimate":-0.9508,"consensus_eps_actual":-1.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105809,"accession_number":"0001104659-26-020667","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Palvella Therapeutics raises ~$187.3M in public offering of 1.6M shares at $125/sh","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwriting agreement with TD Securities, Cantor Fitzgerald, and Stifel for 1,600,000 shares at $125.00 each.","Underwriters have 30-day option to purchase up to an additional 240,000 shares at same price.","Net proceeds estimated at $187.3M after underwriting discounts and expenses.","Proceeds to support QTORIN rapamycin and pitavastatin programs, R&D, and working capital.","Closing expected on or about February 27, 2026, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105808,"accession_number":"0001193125-26-065308","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Palvella announces Phase 3 SELVA topline results for QTORIN in lymphatic malformations; specifics not in filing excerpt","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Topline data from Phase 3 SELVA study of QTORIN 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations announced on Feb 24, 2026.","Investor conference call held at 8:00 a.m. ET; presentation slides furnished as Exhibit 99.1.","Exact efficacy and safety endpoints not disclosed in this filing excerpt; full results expected in the presentation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105807,"accession_number":"0001193125-26-065159","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Palvella Phase 3 SELVA study of QTORIN rapamycin meets primary endpoint with p<0.001; NDA planned H2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint achieved: mean +2.13 improvement on mLM-IGA (p<0.001); all secondary endpoints met (p<0.001).","86% of completers rated 'Much Improved' or better; 95% improved at least 1 point.","Well-tolerated: no drug-related SAEs; systemic rapamycin levels <2 ng/mL at all timepoints.","NDA submission to FDA planned H2 2026; potential approval H1 2027 for first approved therapy for microcystic LMs.","98% of eligible participants chose to continue in extension period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105806,"accession_number":"0001104659-26-019143","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Palvella Therapeutics reports preliminary Dec 31, 2025 cash of $55.9M","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Preliminary unaudited cash, cash equivalents and marketable securities as of Dec 31, 2025: $55.9 million.","Amount subject to change upon completion of financial close procedures; not audited by Ernst & Young.","No other financial results provided; full year 2025 results pending."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105805,"accession_number":"0001193125-26-029341","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2026-01-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Palvella makes corporate presentation available; no new specifics disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation titled 'First-in-disease therapies for rare diseases' dated January 2026.","No financial results, clinical data, or guidance changes included in the provided excerpt.","Filing does not contain material new information beyond the presentation's availability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105804,"accession_number":"0001193125-26-009724","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Palvella posts corporate presentation; no new disclosures","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Corporate presentation posted on company website on January 12, 2026.","Presentation title: \"First-in-disease therapies for patients with rare diseases.\"","Company will use the presentation in investor meetings; no financial or pipeline updates in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122088,"accession_number":"0001104659-25-120789","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Palvella Phase 2 TOIVA study: 73% of patients improved; plans FDA discussions for Breakthrough Therapy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["73% (11/15) improved on Overall cVM-IGA at Week 12; 67% rated \"Much Improved\" or \"Very Much Improved\".","Statistical significance on multiple endpoints, including Overall cVM-IGA (p<0.001) and PGI-C (p<0.001).","QTORIN rapamycin generally well-tolerated; no drug-related SAEs; most common AE application site erythema (25%).","Company plans near-term FDA discussions for Breakthrough Therapy Designation and Phase 3 pivotal study.","Potential first FDA-approved therapy for cutaneous venous malformations affecting >75,000 patients in US."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122087,"accession_number":"0001193125-25-274378","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Palvella Q3 net loss $11.3M; cash $63.6M; Phase 2/3 readouts on track for Dec 2025 and Q1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss per share $1.03 (basic/diluted) vs $3.94 a year ago; R&D expense rose to $6.5M.","Cash & equivalents $63.6M, expected to fund operations into H2 2027.","Phase 2 TOIVA (cutaneous VMs) top-line results expected mid-December 2025.","Phase 3 SELVA (microcystic LMs) top-line results expected Q1 2026.","Expanded pipeline: angiokeratomas and QTORIN pitavastatin for DSAP; Phase 2 start H2 2026; David Osborne appointed CINO."],"consensus_eps_estimate":-0.8551,"consensus_eps_actual":-2.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122086,"accession_number":"0001104659-25-106591","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Palvella announces QTORIN pitavastatin for DSAP; Phase 2 trial planned H2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New candidate targets DSAP, a rare genetic skin disease with no FDA-approved therapies.","DSAP affects an estimated >50,000 diagnosed U.S. patients and is premalignant.","Company plans to meet FDA in H1 2026; Phase 2 trial initiation expected H2 2026.","QTORIN pitavastatin designed to inhibit the mevalonate pathway, the causal driver of DSAP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138794,"accession_number":"0001104659-25-092681","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2025-09-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Palvella expands QTORIN rapamycin program into angiokeratomas, plans Phase 2 in H2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["No FDA-approved therapies exist for clinically significant angiokeratomas, which affect >50,000 diagnosed U.S. patients.","Phase 2 trial of QTORIN rapamycin for angiokeratomas planned to start H2 2026; FDA meeting expected H1 2026.","Ongoing Phase 3 SELVA study for microcystic lymphatic malformations: top-line results Q1 2026; TOIVA Phase 2 results mid-Dec 2025.","Angiokeratomas recently classified as isolated lymphatic malformation by ISSVA in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138793,"accession_number":"0001104659-25-086685","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Palvella posts updated corporate presentation; no material new disclosures","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed an 8-K under Item 7.01 furnishing a corporate presentation dated September 2025.","Presentation describes first-in-disease therapies for rare genetic skin diseases.","No financial results, pipeline updates, or guidance changes disclosed in the filing.","Presentation will be used in investor meetings going forward."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138792,"accession_number":"0000950170-25-108422","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Palvella Q2 net loss $9.5M; Phase 3 LM trial enrollment exceeded target by 25%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 3 SELVA enrolled 51 subjects (target 40); top-line results expected Q1 2026.","Cash $70.4M; expected to fund operations into second half of 2027.","Net loss $9.5M ($0.86/share) vs $4.4M ($2.47); R&D and G&A up due to trial costs.","Company plans to announce third QTORIN rapamycin indication and second platform candidate before year-end 2025.","Appointed Ashley Kline as Chief Commercial Officer; added to Russell 2000/3000 indexes."],"consensus_eps_estimate":-0.7556,"consensus_eps_actual":-1.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156247,"accession_number":"0001104659-25-058532","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Palvella shareholders elect Heron, Wessel as Class II directors; ratify EY","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elaine J. Heron elected with 6,647,082 votes for, 1,255 withheld; Tadd S. Wessel with 6,487,034 for, 161,303 withheld.","Ratification of Ernst & Young as independent auditor for 2025: 7,299,907 for, 8,352 against, 7,334 abstain.","Advisory approval of 2024 named executive officer compensation: 6,550,393 for, 61,078 against, 36,866 abstain.","Broker non-votes on proposals 1 and 3 were 667,256."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156246,"accession_number":"0000950170-25-071988","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Palvella Phase 3 SELVA enrollment surpasses target; cash $75.6M extends runway into H2 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 3 SELVA for microcystic LM exceeded 40-patient enrollment; closes June 2025, top-line Q1 2026.","Phase 2 TOIVA for cutaneous VM enrolled first patients; top-line results on track for Q4 2025.","Cash and equivalents $75.6M at March 31, 2025; funds operations into second half of 2027.","Net loss $8.2M ($0.74 per share) vs $2.7M loss in prior-year period; R&D $4.1M, G&A $3.8M.","Patent granted for QTORIN rapamycin in microcystic LM; IP extends into 2038."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174708,"accession_number":"0000950170-25-047206","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Palvella Therapeutics reports FY2024 net loss $17.4M, cash $83.6M; SELVA top-line Q1 2026 on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $17.4M ($7.83/share) vs net income $17.9M in FY2023; R&D expense $8.2M, G&A $5.9M.","Cash and equivalents $83.6M, expected to fund operations into H2 2027.","Completed merger and $78.9M private placement in Dec 2024 with BVF, Frazier Life Sciences.","Phase 3 SELVA top-line Q1 2026; Phase 2 TOIVA top-line Q4 2025; both for QTORIN rapamycin.","Plans to expand QTORIN pipeline with new indication and product candidate in H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174707,"accession_number":"0001437749-25-006013","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Palvella Therapeutics posts corporate presentation on website; no specific new financial details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company posted corporate presentation to website on March 4, 2025, for use in investor meetings.","Presentation furnished as Exhibit 99.1 under Regulation FD; not deemed filed.","Exhibit provided as an image without extractable text; no quantitative updates available from filing.","No earnings, M&A, leadership changes, or other material events reported in this 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174706,"accession_number":"0001437749-25-000924","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Palvella posts corporate presentation for investor meetings; details not provided in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed under Item 7.01; corporate presentation posted to company website on Jan 13, 2025.","Presentation will be used in meetings with investors, but no specific financial data disclosed in the filing text.","The exhibit only contains 'Image Exhibit' placeholder; no quantitative or strategic updates visible.","No guidance, pipeline milestones, or financial results were included in the 8-K or its exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191661,"accession_number":"0001437749-24-037515","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["1.01","2.01","5.06","3.02","3.03","5.01","5.02","5.03","5.05","8.01","9.01"],"status":"ready","headline":"Palvella completes merger with Pieris, raises $78.9M PIPE, ticker changes to PVLA","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger closed Dec 13, 2024; Former Palvella survives as wholly-owned subsidiary; name changed to Palvella Therapeutics, Inc.","PIPE financing raised $78.9M: $60.0M cash + conversion of $18.9M convertible notes; 3.17M shares and 2.47M pre-funded warrants issued.","Post-merger shares outstanding ~11.2M; Former Palvella securityholders own 81.61% on fully diluted basis; legacy Pieris stockholders own 18.39%.","CVRs issued to pre-merger Pieris stockholders, entitling them to future payments from certain strategic partner agreements and tax credits.","New business is clinical-stage rare-disease skin therapeutics; lead program QTORIN rapamycin for vascular malformations; ticker changes to PVLA Dec 16."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191664,"accession_number":"0001437749-24-037350","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2024-12-12T23:59:59+00:00","items":["3.03","5.07","5.02","5.03","8.01","9.01"],"status":"ready","headline":"Stockholders approve merger with Palvella; authorized shares increased 53x to 200M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger expected to close Dec. 13; pre-merger stockholders receive Contingent Value Rights.","Authorized shares increased from 3.75M to 200M; Series F Preferred redeemed for $0.01.","Proposal to issue shares in merger approved: 718,345 for, 4,199 against, 294,890 broker non-votes.","Name change to Palvella Therapeutics, Inc. and 2024 Equity Incentive Plan approved.","All proposals approved by requisite votes; no adjournment needed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191663,"accession_number":"0001437749-24-036506","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2024-12-03T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Pieris supplements proxy for Palvella merger after 9 shareholder demands and 2 lawsuits","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Annual meeting results: Kiritsy and Kiener elected directors; Ernst & Young ratified; say-on-pay approved.","Received 9 demands and 2 lawsuits alleging insufficient merger disclosures; Pieris denies liability but added supplemental info.","Supplemental disclosures include updated financial analysis tables, Palvella projections probability-adjusted at 65%, and Transaction Committee fees.","No action required for stockholders who already submitted proxies; Pieris urges reading the full proxy statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191662,"accession_number":"0001437749-24-030559","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2024-10-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Palvella (merger target of Pieris) awarded up to $2.6M FDA grant for Phase 3 rare skin disease trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA Office of Orphan Products Development awarded Palvella up to $2.6M over 4 years to support Phase 3 SELVA trial of QTORIN rapamycin gel for microcystic lymphatic malformations.","Program has FDA Breakthrough Therapy and Fast Track designations; trial is single-arm, baseline-controlled.","Grant one of seven awarded out of 51 applications in FY2024; underscores high unmet need in rare genetic skin disease.","Positive development for Palvella, which is being acquired by Pieris Pharmaceuticals via merger announced July 23, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208130,"accession_number":"0001437749-24-025565","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["1.01","5.03","3.02","3.03","9.01"],"status":"ready","headline":"Pieris issues special voting preferred to Chairman to secure authorized share increase vote","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 1 share of Series F Preferred to Chairman James Geraghty for $1 cash; preferred has 25M votes.","Preferred votes only on proposal to increase authorized common shares, in proportion to common votes.","No conversion, dividends, or liquidation rights; redeemable for $0.01 upon authorized share increase or Board order.","The authorized share increase is to facilitate the proposed merger with Palvella Therapeutics.","The preferred ensures a favorable vote on the authorized share increase, a key step in the merger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208129,"accession_number":"0001437749-24-023301","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2024-07-24T23:59:59+00:00","items":["1.01","3.02","5.02","8.01","9.01"],"status":"ready","headline":"Pieris to merge with Palvella in all-stock deal; Palvella holders to own 82%; PIPE raises $78.9M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger values Pieris at ~$21M and Palvella at ~$95M; pre-PIPE, Pieris stockholders hold ~18% of combined company.","PIPE financing of ~$78.9M led by BVF Partners; investors buy ~3.15M shares plus pre-funded warrants.","Each Pieris share receives one CVR entitling holders to future milestones/royalties from legacy partnered assets.","Chief Development Officer Shane Olwill to depart effective Oct 31, 2024; receives €417,800 severance.","Combined board to have 5 directors: 4 from Palvella (Kaupinen, Davis, Jenkins, Wessel), 1 from Pieris (Kiritsy)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208128,"accession_number":"0001437749-24-022188","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["1.02","8.01","9.01"],"status":"ready","headline":"Pieris Pharmaceuticals' Servier collaboration terminated; S095012 Phase 1 halted on safety concern","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Servier terminated license/collaboration agreement effective Dec 27, 2024, citing a potential safety concern in the S095012 Phase 1 study.","Pieris will discontinue all development of S095012; no further pursuit of the asset.","Non-exclusive Anticalin platform license also terminates with the collaboration agreement.","Pieris remains eligible for milestones from Boston Pharma and Pfizer partnerships on other 4-1BB bispecific assets: up to $200M development and >$415M commercial milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225687,"accession_number":"0001437749-24-015466","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Pieris Pharmaceuticals regains compliance with Nasdaq minimum bid price rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on May 7, 2024 confirming compliance with Listing Rule 5550(a)(2).","Closing bid price above $1.00 for 10 consecutive business days (April 23 to May 6, 2024).","Matter is now closed; no further action required by the company.","Stock symbol: PIRS, traded on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225686,"accession_number":"0001437749-24-012442","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2024-04-18T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"Pieris Pharmaceuticals announces 1-for-80 reverse stock split to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at ratio 1-for-80 effective 5:00 pm ET on April 22, 2024; begins trading split-adjusted on April 23 under symbol PIRS.","Outstanding shares reduced from 98,935,025 to approximately 1,236,688; authorized common shares decreased from 300M to 3.75M.","Split aims to raise bid price above $1.00 per share and meet Nasdaq Listing Rule 5550(a)(2) minimum bid price requirement.","No fractional shares issued; fractional interests rounded up to one whole share. CUSIP changes to 720795202.","All outstanding options, warrants, and preferred stock conversion terms adjusted proportionately per their governing documents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244844,"accession_number":"0001437749-24-009491","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2024-03-27T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Pieris restructures to capture partnered milestones; ends R&D, cuts workforce, cash $26.4M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["As of Dec 31, 2023, cash and investments $26.4M; cost cuts expected to extend runway into 2027.","All R&D activities to cease by mid-2024; additional workforce and board reductions planned in Q2 2024.","Eligible for up to $75M in near-term milestones from Pfizer, Boston Pharmaceuticals, and Servier partnerships.","Total potential milestones: up to $275M development and over $500M commercial across partnered 4-1BB bispecific programs.","Company may pursue milestone/royalty monetization or cash dividends in future."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262291,"accession_number":"0001437749-23-035107","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2023-12-21T23:59:59+00:00","items":["1.02","9.01"],"status":"ready","headline":"Pieris terminates German lease; pays €9.7M to exit ~$22M remaining obligations","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease termination effective Dec 31, 2023; fee of ~€9.7M paid to landlord.","Remaining lease payments totaled ~$18.4M, plus ~$3.9M for expansion through 2036.","Pieris vacates 105,000 sq ft lab/office in Hallbergmoos, retains equipment.","Limited use of property permitted until June 30, 2024 at no extra cost.","Part of strategic cost-reduction plan; security deposit to be returned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279482,"accession_number":"0001437749-23-024952","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K/A","filed_at":"2023-08-31T23:59:59+00:00","items":["2.05","9.01"],"status":"ready","headline":"Pieris adds $3.4M retention & severance costs to July 2023 restructuring estimate","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Compensation Committee approved retention benefits for non-executive employees on Aug 30, 2023.","Total estimated retention, severance and related costs now ~$3.4M through Q2 2024.","This amount is in addition to severance costs originally reported in the July 18, 2023 8-K.","Amendment filed solely to update cost estimates; no other changes to prior disclosures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279484,"accession_number":"0001437749-23-020094","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2023-07-18T23:59:59+00:00","items":["1.02","2.02","2.05","8.01","9.01"],"status":"ready","headline":"Pieris terminates AstraZeneca deal, cuts 70% workforce, explores strategic alternatives","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AstraZeneca terminates R&D collaboration effective Oct 15, 2023 due to non-clinical safety findings in elarekibep toxicology study.","Workforce reduced by ~70%; expects ~$3.4M severance costs in Q3 2023.","Cash, equivalents, investments ~$54.9M as of June 30, 2023 (preliminary).","Pieris hires Stifel as financial advisor to explore strategic alternatives including M&A, licensing, or sale.","Focus shifted to advancing cinrebafusp alfa, PRS-220, PRS-400; no assurance of transaction outcome."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279483,"accession_number":"0001437749-23-019831","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2023-07-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Chief Business Officer Ahmed Mousa resigns to become CEO of Vicore Pharma","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ahmed Mousa to resign as SVP, Chief Business Officer, General Counsel & Corporate Secretary effective September 11, 2023.","Resignation to become CEO of Vicore Pharma Holding AB; no disagreement with Pieris on any matter.","CEO Stephen Yoder will oversee corporate and business development following Mousa's departure.","Mousa expected to serve as strategic advisor for a transition period subject to mutual terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297881,"accession_number":"0001437749-23-018518","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2023-06-26T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Stockholders approve 6M share increase under 2020 equity plan and adoption of 2023 ESPP","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At June 21 annual meeting, stockholders approved amendment to 2020 equity incentive plan adding 6,000,000 shares.","Stockholders approved the 2023 Employee Stock Purchase Plan.","Elected directors Stephen S. Yoder, Michael Richman, and Matthew L. Sherman as Class III directors.","Ratified Ernst & Young as independent auditor for FY2023; approved say-on-pay compensation on non-binding basis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297880,"accession_number":"0001437749-23-017908","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2023-06-21T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"AstraZeneca discontinues Phase 2a trial of elarekibep; lung findings from toxicology study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AstraZeneca ceases dosing in clinical studies of elarekibep (IL-4Rα inhibitor for asthma) due to lung pathology from a 13-week GLP toxicology study.","Findings include inflammation-mediated lung tissue damage, not dose-related; no clinical observations in study.","Pieris to expedite review of program implications and reassess corporate priorities before further update.","Cash balance of $53.2 million as of May 31, 2023 (unaudited).","Decision independent of Phase 2a data; findings do not support long-term use or later-stage development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297879,"accession_number":"0001437749-23-016922","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2023-06-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Pieris discontinues respiratory collaboration with Genentech for scientific reasons","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Pieris and Genentech jointly ended the respiratory program in May 2023.","Program aimed at locally delivered respiratory therapies using Pieris' Anticalin technology.","Discontinuation attributed to scientific reasons; no financial terms disclosed.","Pieris furnished a June 2023 investor presentation (Exhibit 99.1) with no updated guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297878,"accession_number":"0001193125-23-149296","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2023-05-19T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Pieris receives Nasdaq bid-price deficiency notice; 180-day cure period","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Closing bid price below $1.00 for 30 consecutive business days triggers deficiency under Nasdaq Listing Rule 5550(a)(2).","Company has until November 13, 2023 to regain compliance; needs $1.00+ close for 10 consecutive days.","If not cured by initial date, may be eligible for additional 180-day period if other listing standards are met.","Options being considered include a reverse stock split; no immediate effect on trading under symbol PIRS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297877,"accession_number":"0001437749-23-013408","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Pieris Q1 net loss widens to $13.2M; elarekibep Phase 2a data expected mid-2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2023 net loss of $13.2M ($0.45/share) vs. $5.1M ($0.07) in Q1 2022; cash $48.4M.","Elarekibep Phase 2a enrollment ongoing; topline data by mid-2024; AstraZeneca adding sites and geographies.","PRS-220 Phase 1 results expected H2 2023; PRS-400 toward candidate nomination H2 2023.","Cinrebafusp alfa in 2L+ HER2+ gastric cancer: 100% ORR in 5 patients; enrollment stopped for strategic reasons.","Seagen initiated Phase 1 for SGN-BB228 (CD228/4-1BB); $5M milestone paid."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":1936000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318128,"accession_number":"0001437749-23-008303","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2023-03-29T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Pieris Pharma reports FY2022 net loss $33.3M; cash down to $59.2M; elarekibep data delayed to mid-2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $33.3M ($0.45/share) vs $45.7M ($0.71) in 2021; R&D expense fell to $53.0M from $66.7M.","Cash, cash equivalents and investments $59.2M at Dec 31, 2022, down from $117.8M; company funded for >12 months.","Elarekibep Phase 2a asthma data now expected mid-2024; AstraZeneca adding >100 sites to complete trial.","PRS-220 Phase 1 IPF topline results expected H2 2023; PRS-400 advancing toward candidate nomination in 2023.","Seagen initiated Phase 1 for SGN-BB228, triggering $5M milestone; Servier discontinued PRS-352."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318127,"accession_number":"0001437749-23-000801","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2023-01-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Pieris receives $5M milestone from Seagen for Phase 1 start of CD228 x 4-1BB bispecific SGN-BB228","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Achieved $5M milestone from Seagen upon first patient dosed in Phase 1 study of SGN-BB228 (PRS-346).","Phase 1 trial (NCT05571839) evaluates SGN-BB228 in advanced melanoma and other solid tumors.","This is the first clinical start in Pieris' collaboration with Seagen; two additional programs ongoing.","Pieris has an opt-in option for U.S. co-promotion on one program in the collaboration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336410,"accession_number":"0001437749-22-026051","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2022-11-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Pieris Pharmaceuticals increases ATM offering capacity to $75M under amended Jefferies agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["As of Nov 4, 2022, Pieris had sold $33.6M of stock under the prior $50M ATM program.","Amendment raises aggregate offering amount to $75M, exclusive of shares previously sold.","Jefferies will use commercially reasonable efforts for at-the-market sales on Nasdaq.","Company is not obligated to sell any shares; other terms of the Sales Agreement unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336409,"accession_number":"0001437749-22-025458","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2022-11-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Pieris Q3 net loss $9.7M ($0.13/sh); cash at $69.8M, funded into Q2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.7M ($0.13 per share) vs $16.5M ($0.24) in Q3 2021.","Cash and investments $69.8M at Sept 30, down from $117.8M at Dec 31, 2021; company expects funding into Q2 2024.","R&D expense $13.6M (down from $18.9M); G&A $3.9M (down from $4.1M).","Elarekibep Phase 2a asthma study enrollment continues; topline FEV1 results expected by Q3 2023.","PRS-220 Phase 1 first subject dosed; IND accepted for SGN-BB228; PRS-342 Phase 1 start within 6 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":20056000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336408,"accession_number":"0001437749-22-025278","cik":1583648,"company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","form_type":"8-K","filed_at":"2022-11-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Pieris doses first subject in Phase 1 trial of inhaled CTGF inhibitor PRS-220 for IPF","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First subject dosed in Phase 1 dose-escalation study of PRS-220, an inhaled Anticalin protein targeting CTGF.","Study evaluating safety, tolerability, and PK in healthy volunteers; results expected in 2023.","IPF affects over 3 million patients worldwide; median survival 3-5 years from diagnosis.","PRS-220 is the second inhaled respiratory program Pieris has brought into the clinic.","CEO Stephen Yoder highlights potential for meaningful improvement in quality of life for IPF patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1677037066.4405212,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-11-01T23:59:59+00:00|336408"}